Athira Pharma, Inc. (NASDAQ:ATHA) Stock Holdings Cut by BML Capital Management LLC

BML Capital Management LLC lessened its position in Athira Pharma, Inc. (NASDAQ:ATHA) by 14.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,454,362 shares of the company’s stock after selling 250,000 shares during the quarter. Athira Pharma comprises 2.7% of BML Capital Management LLC’s holdings, making the stock its 9th largest position. BML Capital Management LLC owned 3.82% of Athira Pharma worth $3,534,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in ATHA. Clarius Group LLC purchased a new position in shares of Athira Pharma in the third quarter valued at approximately $80,000. Acuitas Investments LLC purchased a new position in shares of Athira Pharma in the third quarter valued at approximately $302,000. Marquette Asset Management LLC purchased a new position in Athira Pharma during the third quarter worth approximately $62,000. Barclays PLC lifted its position in Athira Pharma by 99.1% during the third quarter. Barclays PLC now owns 435,841 shares of the company’s stock worth $880,000 after buying an additional 216,933 shares in the last quarter. Finally, Nan Fung Group Holdings Ltd lifted its position in Athira Pharma by 1,429.4% during the third quarter. Nan Fung Group Holdings Ltd now owns 180,000 shares of the company’s stock worth $364,000 after buying an additional 168,231 shares in the last quarter. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Stock Performance

Shares of Athira Pharma stock opened at $2.04 on Wednesday. Athira Pharma, Inc. has a one year low of $1.33 and a one year high of $4.30. The company has a market cap of $78.19 million, a price-to-earnings ratio of -0.66 and a beta of 2.78. The business’s 50 day moving average price is $2.94 and its 200 day moving average price is $2.47.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Thursday, February 22nd. The company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.25. On average, analysts predict that Athira Pharma, Inc. will post -2.86 EPS for the current fiscal year.

Athira Pharma Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.